Table 5. Details of parenteral anticoagulation therapy given alone or prior to oral anticoagulation in the period from baseline up to hospital discharge or 14 days after diagnosis (whichever was later).
| Group A IDDVT a N = 1,016 |
Group B PDVT ± DDVT b N = 2,305 |
Group C PE ± any DVT N = 2,451 |
Total N = 5,772 |
|
|---|---|---|---|---|
| Details of parenteral anticoagulation therapy alone | ||||
| Parenteral therapy, n (%) | 200 (19.7) [17.3–22.3] |
480 (20.8) [19.2–22.5] |
433 (17.7) [16.2–19.2] |
1,113 (19.3) |
| UFH, n (%) | 7 (0.7) [0.3–1.4] |
27 (1.2) [0.8–1.7] |
71 (2.9) [2.3–3.6] |
105 (1.8) Y |
| LMWH, n (%) | 195 (19.2) [16.8–21.8] |
472 (20.5) [18.8–22.2] |
416 (17.0) [15.5–18.5] |
1,083 (18.8) |
| Frequency c | ||||
| QD | 131 (67.2) [60.1–73.7] |
262 (55.5) [50.9–60.1] |
184 (44.2) [39.4–49.2] |
577 (53.3) Y |
| BID | 64 (32.8) [26.3–39.9] |
206 (43.6) [39.1–48.3] |
224 (53.8) [48.9–58.7] |
494 (45.6) Y |
| Other or missing | 0 | 4 (0.8) [0.2–2.2] |
8 (1.9) [0.8–3.8] |
12 (1.1) |
| Fondaparinux, n (%) | 4 (0.4) [0.1–1.0] |
9 (0.4) [0.2–0.7] |
9 (0.4) [0.2–0.7] |
22 (0.4) |
| Details of parenteral anticoagulation therapy prior to oral anticoagulant therapy | ||||
| Parenteral therapy, n (%) | 492 (48.4) [45.3–51.5] |
1,230 (53.4) [51.3–55.4] |
1,455 (59.4) [57.4–61.3] |
3,177 (55.0) |
| UFH, n (%) | 58 (5.7) [4.4–7.3] |
322 (14.0) [12.6–15.5] |
380 (15.5) [14.1–17.0] |
760 (13.2) |
| LMWH, n (%) | 435 (42.8) [39.7–45.9] |
925 (40.1) [38.1–42.2] |
1,203 (49.1) [47.1–51.1] |
2,563 (44.4) |
| Frequency c | ||||
| QD | 215 (49.4) [44.6–54.2] |
366 (39.6) [36.4–42.8] |
361 (30.0) [27.4–32.7] |
942 (36.8) YY |
| BID | 211 (48.5) [43.7–53.3] |
540 (58.4) [55.1–61.6] |
809 (67.2) [64.5–69.9] |
1,560 (60.9) YY |
| Other or missing | 4 (0.9) [0.3–2.3] |
9 (1.0) [0.4–1.8] |
9 (0.7) [0.3–1.4] |
22 (0.4) |
| Fondaparinux, n (%) | 8 (0.8) [0.3–1.5] |
25 (1.1) [0.7–1.6] |
39 (1.6) [1.2–2.3] |
72 (1.2) |
Abbreviations: BID, twice daily; DDVT, distal DVT; DVT, deep vein thrombosis; IDDVT, isolated DDVT; LMWH, low-molecular-weight heparin; PDVT, proximal DVT; PE, pulmonary embolism; QD, once daily; UFH, unfractionated heparin.
Notes: Values in square brackets are 95% confidence intervals. Bold font indicates 95% confidence intervals which had no overlap between group A and either group B or group C or both; Y indicates no overlap with one other group; YY indicates no overlap with two other groups.
a
No iliac vein or proximal lower limb DVT, and no PE.
b
Iliac vein or proximal lower limb DVT (popliteal vein and above), but no PE.
c
Percentages were calculated based on the number of patients who received the respective therapy.